This Biotech Had A 'No Good, Very Bad Week' — And It Just Got Worse [Investor's Business Daily]
Acorda Therapeutics, Inc. (ACOR)
Last acorda therapeutics, inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acorda.com/investors
Company Research
Source: Investors Business Daily
Related news Acorda Therapeutics ' ( ACOR ) "no good, very bad week" continued Friday as shares toppled for the ninth straight day after the Food and Drug Administration delayed its Parkinson's disease drug. In morning trading on the stock market today , Acorda stock dipped 3.8%, near 17.40, in higher-than-average volume . Shares have cratered 37% this month amid challenges for its multiple sclerosis drug Ampyra and Inbrija, its Parkinson's treatment. On Thursday, the FDA pushed back its review date for Inbrija to Jan. 5 from Oct. 5 previously. Raymond James analyst Laura Chico noted delays aren't unusual. But the FDA is likely worried about the complexity of Acorda's drug. Inbrija belongs to a drug class known as levodopa, or L-dopa. "In the context of the prior Inbrija RTF (refusal to file), and the fact that L-dopa remains a well-understood molecule, we continue to see this as more complicated than a traditional small molecule submission," Chico said in a note titled "A No Good, V
Show less
Read more
Impact Snapshot
Event Time:
ACOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACOR
News
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Acorda Therapeutics Announces Nasdaq Delisting Notification [Yahoo! Finance]Yahoo! Finance
- Acorda Therapeutics Announces Nasdaq Delisting NotificationBusiness Wire
- CALM,PLAY and VNDA are among after hour movers [Seeking Alpha]Seeking Alpha
ACOR
Sec Filings
- 4/4/24 - Form 8-K
- 3/13/24 - Form 8-K
- ACOR's page on the SEC website